Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press25110.17650/1726-9776-2011-7-3-144-148REVIEWОБЗОРTADALAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY: A REVIEWПРИМЕНЕНИЕ ТАДАЛАФИЛА ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ У ПАЦИЕНТОВ, ПЕРЕНЕСШИХ РАДИКАЛЬНУЮ ПРОСТАТЭКТОМИЮGovorovA. V.ГоворовА. В.
Russian Federation
alexgovorov@newmail.ruPushkarD. Yu.ПушкарьД. Ю.
Russian Federation
alexgovorov@newmail.ruDepartment of Urology of Moscow State University of Medicine and DentistryКафедра урологии Московского государственного медико-стоматологического университета30092011731441480308201403082014https://oncourology.abvpress.ru/oncur/article/view/251

Erectile dysfunction is a frequent complication of radical prostatectomy despite numerous modifications in surgical technique. The term «penile rehabilitation» refers usually to treatments intended to restore functional penile erection after radical prostatectomy. Selective phosphodiesterase type 5 inhibitors are the mainstay of this rehabilitation at present. Tadalafil seems a logical choice for recovering of erectile functionafter radical prostatectomy given its prolonged duration of action. The once-daily dose of tadalafil has the theoretical benefit in terms of safety and separation of medication from sexual activity. In this paper we review the published clinical and basic science research studies on the role of tadalafil in patients with postprostatectomy erectile dysfunction.

Несмотря на постоянное усовершенствование техники радикальной простатэктомии (РПЭ), эректильная дисфункция остается нередким осложнением операции. Термином «пенильная реабилитация» обычно обозначают различные виды терапии, направленные на восстановление эректильной функции после РПЭ. Большинство программ реабилитации включает назначение селективных ингибиторов фосфодиэстеразы 5-го типа (иФДЭ-5). В настоящее время тадалафил имеет преимущество перед другими иФДЭ-5 вследствие длительного периода полувыведения, а также наличия формы препарата для ежедневного приема, позволяющей исключить взаимосвязь сексуальной активности с приемом лекарства и благодаря уменьшенной дозировке теоретически меньшую вероятность побочных эффектов лечения. В данном обзоре литературы проанализированы клинические и фундаментальные исследования роли тадалафила в терапии эректильной дисфункции после РПЭ.

prostate cancerradical prostatectomyerectile dysfunctionpenile rehabilitationtadalafilрак предстательной железырадикальная простатэктомияэректильная дисфункцияпенильная реабилитациятадалафил1. Walsh P.C., Donker P.J. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492–7.Walsh P.C., Donker P.J. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492–7.2. Montorsi F., Briganti A., Salonia A. et al. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004;45:123–33.Montorsi F., Briganti A., Salonia A. et al. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004;45:123–33.3. Mulhall J., Glina S. Radical pelvic surgery-associated sexual dysfunction. In: Porst H., Buvat J., editors. Standard practice in sexual medicine. Boston: Blackwell, 2006; p.210–24.Mulhall J., Glina S. Radical pelvic surgery-associated sexual dysfunction. In: Porst H., Buvat J., editors. Standard practice in sexual medicine. Boston: Blackwell, 2006; p.210–24.4. Hatzimouratidis K., Burnett A.L., Hatzichristou D. et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009;55:334–47.Hatzimouratidis K., Burnett A.L., Hatzichristou D. et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009;55:334–47.5. Leungwattanakij S., Bivalacqua T.J., Usta M.F. et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003;24:239–45.Leungwattanakij S., Bivalacqua T.J., Usta M.F. et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003;24:239–45.6. User H.M., Hairston J.H., Zelner D.J. et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003;169:1175–9.User H.M., Hairston J.H., Zelner D.J. et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003;169:1175–9.7. Mullerad M., Donohue J.F., Li P.S. et al.Mullerad M., Donohue J.F., Li P.S. et al.Functional sequelae of cavernous nerve injury in the rat: is there model dependency? J Sex Med 2006;3:77–83.8. Shindel A.W. 2009 Update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications. J Sex Med 2009;6:1794–808. 9. Carson C.C. PDE5 inhibitors: are there differences? Can J Urol 2006;13(Suppl 1): 34–9.Shindel A.W. 2009 Update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications. J Sex Med 2009;6:1794–808. 9. Carson C.C. PDE5 inhibitors: are there differences? Can J Urol 2006;13(Suppl 1): 34–9.10. Coward R.M., Carson C.C. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008;4:1315–30.Coward R.M., Carson C.C. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008;4:1315–30.11. Forgue S.T., Patterson B.E., Bedding A.W. et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61:280–8.Forgue S.T., Patterson B.E., Bedding A.W. et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61:280–8.12. Eardley I., Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002;56:300–4.Eardley I., Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002;56:300–4.13. Porst H., Padma-Nathan H., Giuliano F. et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121–5.Porst H., Padma-Nathan H., Giuliano F. et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121–5.14. Vignozzi L., Filippi S., Morelli A. et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006;3:419–31.Vignozzi L., Filippi S., Morelli A. et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006;3:419–31.15. Lysiak J.J., Yang S.K., Klausner A.P. et al. Tadalafil increases Akt and extracellular signalregulated kinase ½ activation and prevents apoptotic cell death in the penis following denervation. J Urol 2008;179:779–85.Lysiak J.J., Yang S.K., Klausner A.P. et al. Tadalafil increases Akt and extracellular signalregulated kinase ½ activation and prevents apoptotic cell death in the penis following denervation. J Urol 2008;179:779–85.16. Kovanecz I., Rambhatla A., Ferrini M.G. et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008;101:203–10.Kovanecz I., Rambhatla A., Ferrini M.G. et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008;101:203–10.17. Wang R. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med 2007;4:1085–97.Wang R. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med 2007;4:1085–97.18. Montorsi F., Nathan H.P., McCullogh A. et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind placebo controlled trial. J Urol 2004;172:1036–41.Montorsi F., Nathan H.P., McCullogh A. et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind placebo controlled trial. J Urol 2004;172:1036–41.19. Miles C.L., Candy B., Jones L. et al. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev 2007:CD005540.Miles C.L., Candy B., Jones L. et al. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev 2007:CD005540.20. Brock G.B., McMahon C.G., Chen K.K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332–6.Brock G.B., McMahon C.G., Chen K.K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332–6.21. Велиев Е.И., Лоран О.Б. Лечение эректильной дисфункции после нервосохраняющей радикальной позадилонной простатэктомии. Урология 2006;1:28–33.Велиев Е.И., Лоран О.Б. Лечение эректильной дисфункции после нервосохраняющей радикальной позадилонной простатэктомии. Урология 2006;1:28–33.22. Aydogdu O., Gokce M.I., Burgu B. et al. Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy. Int Braz J Urol 2011;37:336–46.Aydogdu O., Gokce M.I., Burgu B. et al. Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy. Int Braz J Urol 2011;37:336–46.23. Garcia F.J., Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol 2010;20:234–40.Garcia F.J., Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol 2010;20:234–40.24. Montorsi F., Brock G., Lee J. et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;54:924–31.Montorsi F., Brock G., Lee J. et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;54:924–31.25. Bannowsky A., Schulze H., Van der Horst C. et al. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008;101:1279–83.Bannowsky A., Schulze H., Van der Horst C. et al. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008;101:1279–83.26. Padma-Nathan H., McCullogh A.R., Levine L.A. et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008;20:479–86.Padma-Nathan H., McCullogh A.R., Levine L.A. et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008;20:479–86.27. Lee D.J., Cheetham P., Badani K.K. Penile rehabilitation protocol after robot – assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. BJU Int 2009;105:382–8.Lee D.J., Cheetham P., Badani K.K. Penile rehabilitation protocol after robot – assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. BJU Int 2009;105:382–8.28. Salonia A., Gallina A., Zanni G. et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nervesparing radical prostatectomy. Eur Urol 2008;53:564–70.Salonia A., Gallina A., Zanni G. et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nervesparing radical prostatectomy. Eur Urol 2008;53:564–70.29. Aversa A., Greco E., Bruzziches R. et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19:200–7.Aversa A., Greco E., Bruzziches R. et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19:200–7.30. Albersen M., Joniau S., Claes H. et al. Preclinical evidence for the benefits of penile rehabilitation therapy following nervesparing radical prostatectomy. Adv Urol 2008; article ID 594868.Albersen M., Joniau S., Claes H. et al. Preclinical evidence for the benefits of penile rehabilitation therapy following nervesparing radical prostatectomy. Adv Urol 2008; article ID 594868.31. Mulhall J.P. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008;18:613–20.Mulhall J.P. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008;18:613–20.32. Vignozzi L., Filippi S., Morelli A. et al. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 2009;6:1270–83.Vignozzi L., Filippi S., Morelli A. et al. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 2009;6:1270–83.33. Meuleman E.J., Mulders P.F. Erectile function after radical prostatectomy: a review. Eur Urol 2003;43:95.Meuleman E.J., Mulders P.F. Erectile function after radical prostatectomy: a review. Eur Urol 2003;43:95.34. Washington S.L., Shindel A.W. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug design, development and therapy 2010;4:159–71.Washington S.L., Shindel A.W. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug design, development and therapy 2010;4:159–71.35. Сегал А.С., Пушкарь Д.Ю. Новый патогенетический подход, а также способ лечения и профилактики эректильной дисфункции – модулируемая эректильная оксигенация кавернозной ткани полового члена. Урология 2004;5:48–51.Сегал А.С., Пушкарь Д.Ю. Новый патогенетический подход, а также способ лечения и профилактики эректильной дисфункции – модулируемая эректильная оксигенация кавернозной ткани полового члена. Урология 2004;5:48–51.36. Andersson K.-E., De Groat W.C., McVary K.T. et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourology and Urodynamics 2011;30:292–301.Andersson K.-E., De Groat W.C., McVary K.T. et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourology and Urodynamics 2011;30:292–301.